Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

	Application Number Filing Date		10015352	
			2001-12-12	
	First Named Inventor Yosh		niyuki Kaniwa	
	Art Unit		3624	
	Examiner Name	Char	rles R. Kyle	
	Attorney Docket Number		JP920000349	

					U.S.I	PATENTS			Remove		
Examiner Initial*	niner Cite Patent Number Kind Issue Date Name of Patentee or Applicant Rele		Releva	iges,Columns,Lines where elevant Passages or Relevar gures Appear							
	1										
If you wis	h to a	i dd additional U.S. Patei	nt citatio	n informat	tion pl	ease click the	Add button.	_	Add		_
			U.S.P	ATENT A	PPLIC	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	reation Name of Patentee or Applicant Relev				es,Columns,Lines where want Passages or Relevant res Appear		
	1										
If you wis	h to a	dd additional U.S. Publi		p		information p		d button	Add		
Examinor Cite Foreign Document Country Kind Publication Applicant of cited potential Name of Patentee or Applicant of cited Document United Number? Code's Code Date Document Country Figures Appear								evant or Relevant	74		
	1	09-179883	JP	,	A	1997-07-11					V
	2	10-240747	JP	,	A	1998-09-11					V
If you wis	h to a	l dd additional Foreign P	I atent Do	cument ci	tation	information pl	Lease click the Add	button	Add		
			NON	I-PATENT	LITE	RATURE DO	CUMENTS		Remove		_

	Application Number		10015352
INFORMATION DIGGS COURT	Filing Date		2001-12-12
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Yosh	iyuki Kaniwa
(Not for submission under 37 CFR 1.99)	Art Unit		3624
(··-,	Examiner Name Charl		les R. Kyle
	Attorney Docket Numb	er	JP920000349

include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

T5

	1	TAKESHI KAYANO, "Marketing", 1981, Pages 122-126	Z
	2	Japanese Office Action dated April 11, 2006 along with Information Materials for IDS list	Z
If you wisl	h to a	d additional non-patent literature document citation information please click the Add button Add	

publisher, city and/or country where published.

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at year USPTO_GOV or MPEP 901.64. ² Either office that issued the document, by the ho-letter code (WIPO Standard ST3.) ³ For Juapanese platest colouments, by the about soon of the year of the Emporer most procedule the serial number of the platest coloument.

4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ³ Applicant is to place a check mark their if English language translation is attached.

Examiner Cite

Initials* No

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10015352			
Art Unit		2001-12-12			
		iyuki Kaniwa			
		3624			
		les R. Kyle			
Attorney Docket Number		JP920000349			

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
7	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
_	information disclosure statement. See 37 CFR 1 97(eV1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, to father of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/50(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c)(d)

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Gregory M. Plow/	Date (YYYY-MM-DD)	2006-07-10
Name/Print	Gregory M. Plow	Registration Number	43005

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application port to public insepticines or an issuand patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.